Akeso, Inc.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, liver cancer, and esophageal cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and nec… Read more
Akeso, Inc. (AKESF) - Total Assets
Latest total assets as of June 2025: $13.29 Billion USD
Based on the latest financial reports, Akeso, Inc. (AKESF) holds total assets worth $13.29 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Akeso, Inc. - Total Assets Trend (2020–2024)
This chart illustrates how Akeso, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Akeso, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Akeso, Inc.'s total assets of $13.29 Billion consist of 68.1% current assets and 31.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.0% |
| Accounts Receivable | $524.91 Million | 4.1% |
| Inventory | $706.53 Million | 5.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $320.85 Million | 2.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how Akeso, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Akeso, Inc.'s current assets represent 68.1% of total assets in 2024, a decrease from 77.8% in 2020.
- Cash Position: Cash and equivalents constituted 54.0% of total assets in 2024, down from 69.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 3.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 5.5% of total assets.
Akeso, Inc. Competitors by Total Assets
Key competitors of Akeso, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Akeso, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Akeso, Inc. generates 0.17x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Akeso, Inc. is currently not profitable relative to its asset base.
Akeso, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.43 | 4.79 | 2.25 |
| Quick Ratio | 4.01 | 4.43 | 2.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.92 Billion | $ 5.34 Billion | $ 1.70 Billion |
Akeso, Inc. - Advanced Valuation Insights
This section examines the relationship between Akeso, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.72 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | 38.9% |
| Total Assets | $12.75 Billion |
| Market Capitalization | $7.27 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Akeso, Inc.'s assets below their book value (0.57 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Akeso, Inc.'s assets grew by 38.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Akeso, Inc. (2020–2024)
The table below shows the annual total assets of Akeso, Inc. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $12.75 Billion | +38.93% |
| 2023-12-31 | $9.18 Billion | +67.05% |
| 2022-12-31 | $5.50 Billion | +14.36% |
| 2021-12-31 | $4.81 Billion | +24.63% |
| 2020-12-31 | $3.86 Billion | -- |